Ballentine Partners LLC Sells 74 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Ballentine Partners LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 5.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,366 shares of the medical research company’s stock after selling 74 shares during the period. Ballentine Partners LLC’s holdings in IQVIA were worth $324,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Busey Bank lifted its holdings in shares of IQVIA by 10.6% during the third quarter. Busey Bank now owns 2,318 shares of the medical research company’s stock valued at $549,000 after acquiring an additional 223 shares during the period. Silver Oak Securities Incorporated lifted its holdings in IQVIA by 1,281.5% during the 3rd quarter. Silver Oak Securities Incorporated now owns 2,017 shares of the medical research company’s stock valued at $474,000 after purchasing an additional 1,871 shares during the last quarter. Investment Research & Advisory Group Inc. boosted its position in IQVIA by 1.9% in the third quarter. Investment Research & Advisory Group Inc. now owns 17,843 shares of the medical research company’s stock valued at $4,228,000 after buying an additional 328 shares in the last quarter. IFM Investors Pty Ltd grew its stake in IQVIA by 2.3% during the third quarter. IFM Investors Pty Ltd now owns 37,176 shares of the medical research company’s stock worth $8,810,000 after buying an additional 835 shares during the last quarter. Finally, Bogart Wealth LLC increased its holdings in shares of IQVIA by 80.5% during the third quarter. Bogart Wealth LLC now owns 36,566 shares of the medical research company’s stock worth $8,665,000 after buying an additional 16,305 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 1.4 %

Shares of NYSE IQV opened at $217.54 on Tuesday. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The stock has a market cap of $39.66 billion, a P/E ratio of 28.25, a P/E/G ratio of 2.09 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The firm has a 50 day moving average price of $237.12 and a 200 day moving average price of $230.29.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Evercore ISI reduced their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Morgan Stanley boosted their price objective on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Redburn Atlantic began coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Finally, Barclays dropped their target price on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $267.27.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.